VENEZE Peptide Hair Serum vs 2% Minoxidil for Androgenetic Alopecia
ClinicalTrials.gov Studies
Summary
NIH registered a randomized, double-blind Phase 4 clinical trial (NCT07536100) comparing VENEZE peptide hair serum to topical 2% minoxidil in approximately 300 patients with androgenetic alopecia. Participants will be assessed for changes in hair density, hair thickness, and treatment tolerability over the study period. The trial aims to evaluate whether a peptide-based serum offers a viable alternative to standard minoxidil therapy.
What changed
NIH published a new clinical trial registration for a Phase 4 randomized controlled trial evaluating a peptide-based hair serum (VENEZE) against topical 2% minoxidil for androgenetic alopecia. The double-blind study will assess primary endpoints of hair growth, density, and thickness, with secondary safety and tolerability assessments in approximately 300 participants.
Pharmaceutical companies and clinical investigators conducting or sponsoring hair-loss or dermatology trials should monitor enrollment and outcome data, as positive findings could shift standard-of-care expectations for AGA treatment. Trial sponsors should ensure GxP compliance for any peptide-based product undergoing clinical efficacy evaluation.
Archived snapshot
Apr 18, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
VENEZE Peptide Factor Hair Serum Compared With Topical 2% Minoxidil for Androgenetic Alopecia
N/A NCT07536100 Kind: NA Apr 17, 2026
Abstract
This study aims to evaluate the effectiveness and tolerability of a peptide-based hair serum compared with topical minoxidil in patients with androgenetic alopecia. Participants will be randomly assigned, in a double-blind manner, to receive either the peptide hair serum or topical minoxidil. The primary objective is to assess improvement in hair growth over the study period, including changes in hair density and hair thickness. Secondary outcomes will include safety and tolerability assessments. The findings of this study may provide evidence supporting an alternative treatment option for patients with androgenetic alopecia.
Conditions: Androgenetic Alopecia (AGA)
Interventions: Veneze peptide hair serum, Topical minoxidil
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.